Overview

Detailed Summary

Syncom Formulations (India) Limited operates in the Indian Pharmaceutical Industry, manufacturing and marketing over 200 pharmaceutical formulations. The company specializes in tablets, capsules, liquids, injectables, and herbal products.
Syncom has strategically expanded its manufacturing capacity over the years, notably enhancing tablet and capsule production and establishing modern facilities in Pithampur and Palghar.
The company's export operations are robust, with significant international presence across Africa and Asia. It has received notable export orders, indicating strong overseas demand.
Syncom has demonstrated commitment to modernization, as seen through expansion projects enhancing capacity and introducing advanced manufacturing equipment, indicating focus on quality and efficiency.
The introduction of a new division, Cratus Life Care, highlights Syncom's efforts to expand its operational scope and address diverse market segments, including ethical and herbal product lines.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,283 Cr
Volatility: High Risk
P/E Ratio: 18.0
Industry P/E: 32.2
PEG Ratio: 0.5
P/B Ratio: 3.4
52W High: 23.46
52W Low: 10.21

Sales CAGR

1Y: 76.55%
3Y: 28.20%
5Y: 17.63%
10Y: 10.69%

Profit CAGR

1Y: 95.30%
3Y: 35.17%
5Y: 27.95%
10Y: 18.82%

ROE

TTM: 16.66%
3Y: 10.49%
5Y: 10.95%
10Y: 10.26%

ROCE

TTM: 22.00%
3Y: 14.40%
5Y: 14.99%
10Y: 13.81%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
VENUSREM		926.00	1,363 Cr	16.22	2.29	0.00	10.66	13.99	9.93
SAKAR		528.80	1,356 Cr	46.57	4.47	0.00	6.43	8.43	5.62
BETA		1394.40	1,352 Cr	33.18	5.93	0.00	18.96	18.07	8.50
SYNCOMF		14.04	1,283 Cr	18.00	3.39	0.00	16.66	22.00	15.12
HESTERBIO		1429.05	1,257 Cr	28.62	3.72	0.47	12.98	9.93	6.29
JAGSNPHARM		190.30	1,244 Cr	31.38	4.92	1.33	17.30	21.58	13.68
LINCOLN		615.00	1,232 Cr	14.02	1.72	0.29	11.18	15.34	10.28
Median: 7 Co.	—	615.00	1,283 Cr	28.62	3.72	0.00	12.98	15.34	9.93

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	64	65	75	86	102	128	149	117	122	115
Expenses	57	58	65	77	90	113	131	101	103	94
Operating Profit	6.41	7.36	9.42	9.49	12	15	18	16	18	21
OPM %	10.04	11.30	12.63	11.00	11.89	11.55	11.93	13.52	15.12	18.42
Other Income	4.00	4.54	3.10	2.31	4.15	4.04	6.95	6.07	5.25	5.50
Interest	1.08	1.08	1.20	0.39	0.16	0.20	0.12	0.25	0.26	0.26
Depreciation	0.88	1.45	1.30	1.30	1.30	1.31	1.29	1.34	1.35	1.36
Profit Before Tax	8.45	9.36	10	10	15	17	23	20	22	25
Tax %	22.96	25.21	26.22	24.46	25.19	24.68	24.08	22.38	24.68	24.63
Net Profit	6.51	7.00	7.40	7.63	11	13	18	16	17	19
EPS in Rs	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	115	152	174	186	185	220	224	263	465	496
Expenses	104	135	155	167	168	200	205	234	411	435
Operating Profit	11	17	18	18	17	20	20	30	54	60
OPM %	9.28	10.94	10.53	9.85	8.94	9.12	8.75	11.26	11.64	12.20
Other Income	1.15	1.12	1.98	2.67	2.79	12	15	14	17	21
Interest	0.43	0.36	0.21	0.07	0.28	1.93	3.13	4.47	0.86	0.73
Depreciation	2.91	3.07	3.43	3.00	3.12	3.95	4.54	4.72	5.19	5.24
Profit Before Tax	8.45	14	16	16	16	26	27	34	66	76
Tax %	33.06	33.10	37.60	35.68	33.65	24.39	24.47	25.44	24.54	23.98
Net Profit	5.66	9.32	9.76	10	11	20	20	25	49	58
EPS in Rs	2.53	—	—	—	—	—	0.25	0.34	0.57	0.78
Dividend Payout %	857.14	16.81	16.00	15.04	14.81	12.50	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	22	78	78	78	78	86	94	94	94
Reserves	65	17	22	31	39	136	162	194	248
Borrowings	2.05	3.30	6.08	5.62	12	58	83	72	4.58
Other Liabilities	33	42	31	61	50	28	39	44	67
Total Liabilities	123	140	138	175	180	308	378	405	413
Fixed Assets	50	50	46	46	55	47	43	72	78
CWIP	0.00	0.00	0.00	4.72	0.25	6.20	26	0.00	0.00
Investments	6.74	9.31	6.38	23	36	90	111	114	140
Other Assets	66	80	85	101	89	165	197	219	196
Total Assets	123	140	138	175	180	308	378	405	413

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	5.78	6.73	0.19	24	14	16	11	-5.96	23
Cash from Investing Activity	-0.32	-4.28	0.63	-23	-18	-27	-45	83	-18
Cash from Financing Activity	-6.38	-0.93	0.68	-2.41	4.67	8.29	35	-15	-68
Net Cash Flow	-0.92	1.52	1.50	-1.08	0.83	-2.45	0.58	63	-63

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%
FIIs	0.00%	0.00%	0.00%	0.08%	0.09%	0.10%	0.13%	0.11%	0.41%	0.10%	0.26%	0.21%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	49.43%	49.43%	49.43%	49.35%	49.34%	49.33%	49.30%	49.32%	49.02%	49.33%	49.17%	49.21%
Total Shareholders	2,24,925	2,24,252	2,89,982	3,25,761	3,76,530	4,69,242	4,89,520	4,84,529	4,71,066	4,57,364	4,42,280	4,31,690

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd (SYNCOMF) is currently trading at 13.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Syncom Formulations (India) Limited operates in the Indian Pharmaceutical Industry, manufacturing and marketing over 200 pharmaceutical formulations. The company specializes in tablets, capsules, liquids, injectables, and herbal products. Syncom has strategically expanded its manufacturing capacity over the years, notably enhancing tablet and capsule production and establishing modern facilities in Pithampur and Palghar. The company's export operations are robust, with significant international presence across Africa and Asia. It has received notable export orders, indicating strong overseas demand. Syncom has demonstrated commitment to modernization, as seen through expansion projects enhancing capacity and introducing advanced manufacturing equipment, indicating focus on quality and efficiency. The introduction of a new division, Cratus Life Care, highlights Syncom's efforts to expand its operational scope and address diverse market segments, including ethical and herbal product lines.

Over the past 52 weeks, Syncom Formulations (India) Ltd has traded between a low of ₹10.21 and a high of ₹23.46. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Syncom Formulations (India) Ltd has a market capitalization of approximately 1,283.10. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Syncom Formulations (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,283.10 Cr, Syncom Formulations (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Syncom Formulations (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Syncom Formulations (India) Ltd is 18.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The 'Biopharma Shakti' initiative, a ₹10,000 crore program to make India a global biopharma manufacturing hub, is the most significant announcement for the pharmaceutical sector, including companies like Syncom.

Syncom Formulations India Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Syncom Formulations (India) Ltd

What is Syncom Formulations (India) Ltd share price today?

What does Syncom Formulations (India) Ltd do?

What is the 52-week high and low of Syncom Formulations (India) Ltd?

What is the market capitalization of Syncom Formulations (India) Ltd?

Should I consider investing in Syncom Formulations (India) Ltd stock?

Is Syncom Formulations (India) Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Syncom Formulations (India) Ltd belong to and why does it matter?

What is the PE ratio of Syncom Formulations (India) Ltd?

What is the main Union Budget 2026 announcement affecting Syncom Formulations?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Forecasts

Projection

Frequently Asked Questions about Syncom Formulations (India) Ltd

What is Syncom Formulations (India) Ltd share price today?

What does Syncom Formulations (India) Ltd do?

What is the 52-week high and low of Syncom Formulations (India) Ltd?

What is the market capitalization of Syncom Formulations (India) Ltd?

Should I consider investing in Syncom Formulations (India) Ltd stock?

Is Syncom Formulations (India) Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Syncom Formulations (India) Ltd belong to and why does it matter?

What is the PE ratio of Syncom Formulations (India) Ltd?

What is the main Union Budget 2026 announcement affecting Syncom Formulations?

Peers

Price Chart Comparison

Overview

Financial Ratios

Oscillators

Bearish

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Investment Checklist